IN8bio (NASDAQ:INAB) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IN8bio (NASDAQ:INABFree Report) in a research report released on Friday, Benzinga reports. The firm currently has a $12.50 target price on the stock.

Separately, Laidlaw initiated coverage on IN8bio in a report on Monday, March 18th. They set a buy rating and a $7.50 target price on the stock.

Read Our Latest Analysis on IN8bio

IN8bio Stock Performance

INAB opened at $1.00 on Friday. The company has a market cap of $44.12 million, a P/E ratio of -1.10 and a beta of 0.14. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.20. IN8bio has a 52-week low of $0.65 and a 52-week high of $2.48.

IN8bio (NASDAQ:INABGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). As a group, equities analysts anticipate that IN8bio will post -0.6 EPS for the current fiscal year.

Institutional Trading of IN8bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rock Creek Group LP lifted its stake in IN8bio by 98.3% during the 3rd quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock worth $157,000 after acquiring an additional 75,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc grew its holdings in shares of IN8bio by 85.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock worth $109,000 after purchasing an additional 36,179 shares during the last quarter. Finally, AIGH Capital Management LLC acquired a new position in IN8bio during the fourth quarter worth approximately $5,216,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

(Get Free Report)

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.

Featured Articles

Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with's FREE daily email newsletter.